BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemia

Special Reports, B-Cell Malignancies, Volume 1, Issue 1

Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.

Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia, including BTK and PI3K inhibitors.

Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?Read more > >